Received Aug 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
second dose of havrix administered less than one month after the first dose; This non-serious case was reported by a consumer via call center representative and described the occurrence of drug dose administration interval too short in a 20-month-old male patient who received HAV (Havrix) for prophylaxis. Concomitant products included Hepatitis a vaccine inact (Havrix). On 30-JUN-2011, the patient received the 2nd dose of Havrix. On 30-JUN-2011, an unknown time after receiving Havrix, the patient experienced drug dose administration interval too short (Verbatim: second dose of havrix administered less than one month after the first dose). On 30-JUN-2011, the outcome of the drug dose administration interval too short was not applicable. Additional Information: GSK Receipt Date: 23-JUL-2025 The reporter, the mother, called to report that her son, a minor who was 15 years old at the time, had received the second dose of Havrix on 30th June 2011, less than one month after the first dose, which had been received on 23rd June 2011, which led to Drug dose administration interval too short. The product had been verified with the pharmacist on duty at the local pharmacy to be Havrix; however, the pharmacy had not administered the vaccines and had no further information to provide. The reporter stated that the vaccines had been administered to her son at the physician's clinic.